Skip to content

Scleroderma Registry & Repository at the Hospital for Special Surgery

The Scleroderma Registry & Repository

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01656447
Enrollment
300
Registered
2012-08-03
Start date
2006-08-31
Completion date
2030-01-31
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Keywords

Scleroderma, Scleroderma Registry, Hospital for Special Surgery Scleroderma

Brief summary

The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential treatment for this currently untreatable condition.

Detailed description

What will be asked of you: * Completion of 2 health questionnaires * Donation of research bloods. This is optional, but encouraged (if possible). * We also encourage patients who come for initial visits to return so follow-up data can be collected. Benefits to Patients: * The HSS Scleroderma Registry gives patients the opportunity to participate in observational research with the goal of improving the lives of patients in the future. * By donating research bloods and providing clinical information, patients will help generate new knowledge about Scleroderma that can guide the treatment and care of patients afflicted with this rare disease. * Patients will also receive a comprehensive, medical evaluation from an HSS physician who specializes in treating Scleroderma. He or she will provide guidance on treatment options and recommendations for current or upcoming clinical trials. * Physicians will also make patients aware of the resources available to them, including support groups and educational programs.

Interventions

None listed

Sponsors

Hospital for Special Surgery, New York
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals older than 18 years of age with Scleroderma

Exclusion criteria

* Individuals younger than 18 years of age * Individuals older than 18 years of age without Scleroderma

Design outcomes

Primary

MeasureTime frameDescription
Modified Rodnan Skin ScoreBaseline & follow-up visits during regularly scheduled appointments for up to 5 yearsPhysician score of skin thickening over 17 areas of the body.

Secondary

MeasureTime frameDescription
Scleroderma Health Assessment QuestionnaireBaseline & follow-up visits during regularly scheduled appointments for up to 5 yearsPatient questionnaire
Short Form-36Baseline & follow-up visits during regularly scheduled appointments for up to 5 yearsPatient questionnaire

Countries

United States

Contacts

Primary ContactEliza Pelrine, BA
pelrinee@hss.edu(212)774-2123
Backup ContactEmily Bakaj, BA
bakaje@hss.edu(212)774-7620

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026